The treatment for<unk>  consists of prenatal identification and of enzyme replacement therapy. On 12 February 2014, the US Food and Drug Administration approved the drug elosulfase alfa (Vimizim) for treating Type A. Currently, there is no treatment for Type B.
Morquio syndrome
Eiken syndrome
Hapnes Boman Skeie syndrome
Zieve's syndrome
Galloway Mowat syndrome
Schimmelpenning syndrome
Okamoto syndrome
Sanjad-Sakati syndrome